首頁 > 市場調查報告書 > 醫療設備

整形外科

市場調查報告書

商品編碼

1610878

骨科生物製品的全球市場:洞察，競爭情形，市場預測:2030年

Orthobiologics - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年12月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

2023年骨科生物製劑的市場規模為53.3億美元。預計到 2030 年，該市場將達到 68.4 億美元，2024 年至 2030 年的預測期間複合年增長率為 4.44%。由於導致脊椎損傷的外傷和事故病例增加、骨關節炎和類風濕性關節炎等退化性骨疾病盛行率增加以及運動病例增加，骨科生物製劑市場預計將在 2024 年至 2030 年期間增長。生物製品市場在預測期內顯著成長，因為它是需求增加的主要因素。

根據世界衛生組織 (WHO) (2024) 的數據，到 2021 年，全球將有 1,540 萬人患有脊髓損傷。大多數脊髓損傷病例是由創傷或暴力行為（包括跌倒）造成的，因此是可以預防的。此外，到2023年，道路交通事故將成為5-29歲兒童和青少年的第一大死因。情況說明書進一步指出，全球每年有近 2,000 萬至 5,000 萬人因道路交通事故而遭受非致命傷害並致殘。

根據世界衛生組織 (WHO) 數據（2023 年），全球有 3.44 億人患有骨關節炎。在這一人群中，73%的骨關節炎患者年齡超過55歲，其中60%是女性。骨關節炎是一種退化性關節疾病，其特徵是膝關節軟骨破壞，導致疼痛、僵硬和活動範圍減少。據同一來源稱，有 1300 萬人患有類風濕性關節炎。關節內壁發炎和侵蝕，導致軟骨和骨骼逐漸破壞。

骨科生物製劑用於治療各種肌肉骨骼疾病，以促進癒合和緩解症狀。它已被實驗性地用於脊髓損傷，以促進神經再生和修復。在骨關節炎和類風濕關節炎中，富含血小板的血漿和幹細胞等生物製劑旨在減少發炎並支持軟骨修復。對於運動和娛樂損傷，這些治療可以幫助加速恢復和修復受損組織。此外，骨科生物製劑還可透過促進組織再生和減少發炎來治療腰痛和其他肌肉骨骼問題。

因此，在 2024 年至 2030 年的預測期內，上述因素將共同推動整個骨科生物製品市場的發展。

本報告提供全球骨科生物製品市場相關調查，提供市場概要，以及各產品類型，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

Orthobiologics Market by Product Type (Viscosupplementation Products, Demineralized Bone Matrices, Bone Morphogenic Protein, Synthetic Bone Substitutes, Bone Grafts, and Others), Application (Osteoarthritis, Spinal Fusion, Soft-Tissue Injuries, Fracture Recovery, and Maxillofacial & Dental Applications), End-User (Hospitals, Orthopaedic Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the rising number of trauma & accident cases and increase in the prevalence of degenerative bone disorders across the globe

The orthobiologics market was valued at USD 5.33 billion in 2023, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030, to reach USD 6.84 billion by 2030. The orthobiologics market is growing significantly due to the rising number of trauma and accident cases that cause spinal injuries, increase in prevalence of degenerative bone disorders such as osteoarthritis and rheumatoid arthritis, and rising instances of sports-related injuries that are acting as major factors escalating the demand for orthobiologics market during the forecast period from 2024 to 2030.

Orthobiologics Market Dynamics:

According to the World Health Organization (2024) in 2021, 15.4 million people were living with spinal cord injuries globally. Most cases of spinal cord injury result from trauma, including falls, or acts of violence, and are therefore preventable. Moreover, in 2023, it was stated that road traffic injuries were the leading cause of fatality in children and young adults in the age group of 5-29 years. The same factsheet further stated that nearly 20-50 million people suffer from non-fatal injuries in road accidents resulting in a disability as a result of their injury globally each year.

As per data from the World Health Organization (2023), 344 million individuals were affected by osteoarthritis globally. Among this population, 73% of people living with osteoarthritis are older than 55 years, and 60% are female. Osteoarthritis is a degenerative joint disease characterized by the breakdown of cartilage in the knee joint, leading to pain, stiffness, and reduced range of motion. As per the same source, 13 million people were living with rheumatoid arthritis. This causes the joint lining to become inflamed and eroded, leading to progressive destruction of the cartilage and bone.

According to the National Safety Council (2024), it stated that in 2023, emergency departments treated 3.7 million people for injuries related to sports and recreational equipment. The activities most often led to these injuries were exercise, cycling, and basketball. Furthermore, it stated that injuries from exercise and exercise equipment went up by 8% in 2023, with 482,886 injuries compared to 445,642 in 2022. The highest injury rate was among 15 to 24-year-olds.

The World Health Organization in the year 2022 stated that approximately 1.71 billion people were affected by musculoskeletal conditions worldwide. Further it stated that low back pain is the main contributor to the overall burden of musculoskeletal conditions which contributes to 570 million prevalent cases worldwide. Musculoskeletal conditions, affecting a significant portion of the global population, often include low back pain as a major issue.

Orthobiologics are employed in various musculoskeletal conditions to enhance healing and alleviate symptoms. For spinal cord injuries, they are used experimentally to promote nerve regeneration and repair. In osteoarthritis and rheumatoid arthritis, orthobiologics like platelet-rich plasma and stem cells aim to reduce inflammation and support cartilage repair. For sports and recreational injuries, these therapies help accelerate recovery and repair damaged tissues. Additionally, orthobiologics are utilized to treat low back pain and other musculoskeletal issues by promoting tissue regeneration and reducing inflammation.

Therefore, the factors stated above collectively will drive the overall orthobiologics market during the forecast period from 2024 to 2030.

However, the availability of alternative therapies and stringent regulatory approvals among others may limit their end-user base, thus acting as key constraints limiting the growth of the orthobiologics market.

Orthobiologics Market Segment Analysis:

In the product type segment of orthobiologics, the bone grafts category is expected to have a significant revenue share in the year 2023. The rapid growth of this product category can be attributed to the features associated with this category.

The bone grafts provide structural support, promote new bone formation, and facilitate the healing of fractures or defects. Applications include spinal fusions, where bone grafts support vertebral stabilization; repair of complex fractures or bone loss due to trauma and reconstruction following tumor removal.

Additionally, bone grafts are utilized in dental implant procedures and orthognathic surgeries to restore bone volume and function. Their versatility and effectiveness make them essential tools in managing a wide array of orthopedic and dental conditions, enhancing recovery and long-term outcomes.

Rising product developmental activities by the regulatory body are also likely to drive the market for same. For example in February 2022, Orthofix Medical introduced Opus BA, a synthetic bioactive bone graft solution designed for cervical and lumbar spine fusion procedures. This launch marks the company's expansion in synthetic bone growth solutions.

Therefore, owing to all the above-mentioned factors, the demand for the bone grafts category upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the orthobiologics market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall orthobiologics market:

Among all the regions, North America is expected to dominate the orthobiologics market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be ascribed to the growing burden of total knee replacement surgeries due to conditions like gout, increased instances of vertebral compression fractures, and hip fractures, coupled with ongoing advancements in medical technology and a robust healthcare infrastructure in the region that drives the market for orthobiologics during the forecast period from 2024 to 2030.

According to data from the American Academy of Orthopaedic Surgeons in 2024, it stated that over 700,000 total knee replacement surgeries were performed each year in the US. In addition to this, recent updates provided by the Arthritis Society Canada (2022), stated that 1 million Canadians were affected by gout, which is the most common form of inflammatory arthritis. Gout predominantly impacts males more than females, with approximately 4% of men and 1% of women affected. Among the various joints that can be affected, the knee joint is the most commonly involved.

According to the National Institute of Health (2023), it stated that vertebral compression fractures (VCFs) are the most frequently reported type of fragility fracture. In the US, approximately 1 to 1.5 million VCFs occur each year. Studies suggest that about 25% of women aged 50 and older have at least one VCF. Additionally, between 40% and 50% of individuals over the age of 80 are estimated to have experienced a VCF, either as an acute event or discovered incidentally during the evaluation of other health issues.

According to data from the American Academy of Orthopaedic Surgeons (2024), annually, over 300,000 individuals in the U.S. experience a hip fracture, with the majority occurring in those aged 65 and older due to falls in the home or community. In addition to this, the National Institute of Health (2023) stated that in the US, avascular necrosis of the femoral head is estimated to affect between 20,000 and 30,000 new patients each year.

Orthobiologics play a significant role in various orthopedic conditions mentioned above. In total knee replacement surgeries and knee-related issues caused by arthritis or gout, orthobiologics like platelet-rich plasma and stem cells are used to promote cartilage repair, reduce inflammation, and improve healing outcomes. For VCFs, orthobiologics such as bone grafts and bone morphogenetic proteins are utilized to enhance bone healing and support spinal stability. In hip fractures and conditions like avascular necrosis of the femoral head, orthobiologics aid in bone regeneration and improve recovery by promoting blood supply and new bone growth.

Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the orthobiologics market.

Orthobiologics Market key players:

Some of the key market players operating in the orthobiologics market include Medtronic, Stryker, Johnson & Johnson Services, Inc., Arthrex, Inc., Zimmer Biomet, Baxter, Orthofix Medical Inc., TERUMO BCT, INC., Sanofi, Bioventus, Collagen Matrix, Inc., Seikagaku Corporation, NuVasive Inc., Exactech, Inc., Fidia Farmaceutici S.p.A, BONESUPPORT AB, Kuros Biosciences, XTANT MEDICAL, Biomatlante, Globus Medical, and others.

Recent Developmental Activities in the Orthobiologics Market:

In June 2023, BONESUPPORT(TM), an emerging leader in orthobiologics for managing bone injuries, announced the launch of the next generation of the company's breakthrough antibiotic-eluting bone graft substitute, CERAMENT G.
In March 2022, SeaSpine announced the launch of its NorthStar cervical facet fusion and Flash navigation lumbar facet fusion systems. These new offerings were designed to enhance spinal surgery by providing advanced solutions for cervical and lumbar facet fusion procedures.
In July 2021, Orthofix Medical Inc., launched the fiberFUSE strip, an advanced demineralized fiber bone graft solution containing cancellous bone in the US.
In July 2021, RTI Surgical entered into a long-term strategic agreement with Exactech for the development and supply of biologic bone substitutes. As part of the agreement, RTI Surgical acquired Exactech's Optecure(R), a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities.

Key Takeaways from the Orthobiologics Market Report Study

Market size analysis for current orthobiologics market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the orthobiologics market
Various opportunities available for the other competitors in the orthobiologics market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current orthobiologics market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for orthobiologics market growth in the coming future?

Target audience who can be benefited from this Orthobiologics Market Report Study

Orthobiologics product providers
Research organizations and consulting companies
Orthobiologics-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in orthobiologics
Various end-users who want to know more about the orthobiologics market and the latest developments in the orthobiologics market

Frequently Asked Questions for the Orthobiologics Market:

1. What are Orthobiologics?

Orthobiologics are substances used to improve the healing of broken bones and injured muscles, tendons, and ligaments. These products are often made from substances that are naturally found in the body.

2. What is the market for Orthobiologics?

The orthobiologics market was valued at USD 5.33 billion in 2023, growing at a CAGR of 4.44% during the forecast period from 2024 to 2030 to reach USD 6.84 billion by 2030.

3. What are the drivers for the Orthobiologics market?

The orthobiologics market is growing significantly due to the rising number of trauma and accident cases that cause spinal injuries, increase in prevalence of degenerative bone disorders such as osteoarthritis and rheumatoid arthritis, and rising instances of sports-related injuries that are acting as major factors escalating the demand for orthobiologics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Orthobiologics market?

5. Which region has the highest share in the Orthobiologics market?

Among all the regions, North America is estimated to hold a significant revenue share in the orthobiologics market. This can be ascribed to the growing burden of total knee replacement surgeries due to conditions like gout, increased instances of vertebral compression fractures, and hip fractures, coupled with ongoing advancements in medical technology and a robust healthcare infrastructure in the region that drives the market for orthobiologics during the forecast period from 2024 to 2030.

1. Orthobiologics Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Orthobiologics Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Orthobiologics Market Key Factors Analysis

5.1. Orthobiologics Market Drivers
- 5.1.1. Rising number of trauma and accident cases
- 5.1.2. Increase in prevalence of degenerative bone disorders
- 5.1.3. Growing number of sports-related injuries
- 5.1.4. Rising product developmental activities
5.2. Orthobiologics Market Restraints and Challenges
- 5.2.1. Availability of alternative therapies
- 5.2.2. Stringent regulatory approval
5.3. Orthobiologics Market Opportunities
- 5.3.1. Incorporating orthobiologics with 3D printing technology
- 5.3.2. Continuous research and development in advanced cellular therapies

6. Orthobiologics Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Orthobiologics Market Assessment

7.1. By Product Type
- 7.1.1. Viscosupplementation Products
- 7.1.2. Demineralized Bone Matrices
- 7.1.3. Bone Morphogenic Protein
- 7.1.4. Synthetic Bone Substitutes
- 7.1.5. Bone grafts
- 7.1.6. Others
7.2. By Application
- 7.2.1. Osteoarthritis
- 7.2.2. Spinal Fusion
- 7.2.3. Soft-tissue Injuries
- 7.2.4. Fracture Recovery
- 7.2.5. Maxillofacial and Dental Applications
7.3. End-User
- 7.3.1. Hospitals
- 7.3.2. Orthopaedic Clinics
- 7.3.3. Others
7.4. By Geography
- 7.4.1. North America
  - 7.4.1.1. United States Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.1.2. Canada Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.1.3. Mexico Orthobiologics Market Size in USD million (2021-2030)
- 7.4.2. Europe
  - 7.4.2.1. France Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.2.2. Germany Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.2.3. United Kingdom Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.2.4. Italy Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.2.5. Spain Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.2.6. Rest of Europe Orthobiologics Market Size in USD million (2021-2030)
- 7.4.3. Asia-Pacific
  - 7.4.3.1. China Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.3.2. Japan Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.3.3. India Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.3.4. Australia Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.3.5. South Korea Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.3.6. Rest of Asia-Pacific Orthobiologics Market Size in USD million (2021-2030)
- 7.4.4. Rest of the World (RoW)
  - 7.4.4.1. Middle East Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.4.2. Africa Orthobiologics Market Size in USD million (2021-2030)
  - 7.4.4.3. South America Orthobiologics Market Size in USD million (2021-2030)

8. Orthobiologics Market Company and Product Profiles

8.1. Medtronic
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Stryker
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. Johnson & Johnson Services, Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. Arthrex, Inc.
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Zimmer Biomet
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. Baxter
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Orthofix Medical Inc.
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. TERUMO BCT, INC.
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Sanofi
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. Bioventus
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. Collagen Matrix, Inc.
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Seikagaku Corporation
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. NuVasive Inc.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. Exactech, Inc.
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Fidia Farmaceutici S.p.A
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. BONESUPPORT AB
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Kuros Biosciences
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. XTANT MEDICAL
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. Biomatlante
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. Globus Medical
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy